查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1268929

2023-2030 年全球抗生素市場

Global Antibacterial Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球抗菌藥物市場預計將實現利潤豐厚的增長，到 2022 年將達到 438.574 億美元，到 2030 年將達到 633.268 億美元。 全球抗菌藥物市場預計在預測期內（2023-2030 年）的複合年增長率為 4.8%。 主要的區域參與者正在強調新產品的發布以增加銷售額。

例如，2023 年 2 月，日本製藥公司 Shionogi 在丹麥推出了一種抗菌藥物。 FETCROJA（cefiderocol）在丹麥上市，用於治療成人（18 歲及以上）需氧革蘭氏陰性細菌感染，治療選擇有限。 丹麥的推出是在歐洲迅速擴大頭孢地爾可及性的重要一步，在歐洲，抗生素耐藥性感染在全球抗菌藥物市場上呈上升趨勢。

抗菌劑來源於細菌和真菌，通過抑制細胞壁形成、增加細胞膜通透性以及抑制蛋白質合成和核酸代謝等代謝過程發揮作用。 苯氧甲基青黴素和青黴素 V 等抗生素用於治療與細菌有關的疾病。 但是，它不能治療感冒、流感和大多數咳嗽等病毒感染。

此外，預計在預測期內，增加抗菌藥物臨床前開發管道、增加 FDA 批准以及增加主要市場參與者的合作夥伴關係將推動抗菌藥物市場的增長。

市場動態

增加研發合作以解決抗菌素耐藥性 (AMR) 推動市場增長

根據全球抗生素研究與開發夥伴關係 (GARDP)，當細菌隨時間發生變化並且對治療的反應減弱時，就會產生抗生素耐藥性。 每年，數百萬人遭受抗生素耐藥性之苦，近 130 萬人死亡。 此外，世界衛生組織（WHO）已將抗生素耐藥性列為全球十大健康威脅之一，是耐藥性感染的全球大流行。

2023 年 3 月 9 日，全球抗生素研發夥伴關係 (GARDP) 和利物浦大學簽署了一份諒解備忘錄，共同合作開展一個新項目，以解決公共衛生領域的抗菌素耐藥性 (AMR) 問題。

同樣，2023年4月3日，世界衛生組織和GARDP呼籲製造商申請開髮用於治療多重耐藥細菌感染的抗生素“Cefiderocle”。 這是 WHO 藥品資格預審計劃 (PQP) 首次將多種細菌感染納入其工作。 PQP 正在發出邀請，以支持使耐多藥治療變得負擔得起和可及的舉措。

新抗生素開發的挑戰阻礙了抗菌市場的增長

發現和創造新的抗生素很困難，因為研發需要時間和成本，而且失敗的案例很多。 例如，據說開發新的抗生素需要 10-15 年，耗資超過 10 億美元。 此外，後期臨床試驗和首次產品上市後的支出佔所有新藥研發支出的 80%，阻礙了抗菌藥物市場的增長。

COVID-19 影響分析

COVID-19 大流行對抗菌劑市場產生了重大影響。 在醫院和診所，非緊急預約被延遲或推遲，減少了接受適當護理的患者人數。 此外，細菌感染患者可能因害怕感染 COVID-19 而不願就醫。 因此，抗菌藥物市場的收入有所下降，但仍用於 COVID，確保了預測期內市場的穩定增長。

俄烏衝突分析

烏克蘭的醫療保健系統受到俄羅斯入侵的困擾，俄羅斯入侵摧毀了許多設施，並且由於缺乏熟練的醫務人員而可用性有限。 據國家統計，入侵者在烏克蘭東部破壞了505家藥店，摧毀了其中的47家，干擾了烏克蘭政府和其他國家提供的人道主義援助。

此外，在入侵俄羅斯後的 11 天內，藥房銷售額翻了一番，因為大量慢性病患者購買了這種藥物。 抗炎抗風濕藥、C09、鎮痛藥、安定藥、降糖藥、全身抗生素是最常購買的藥物。

從2022年3月開始，烏克蘭醫藥市場銷售額出現明顯下滑，與2021年同期相比，3月下降11%，4月下降32%，5月和6月下降24%。 下降的原因是移民、就業、醫療人道主義援助和國民收入下降。 1 月份為 31%，2 月份為 45%。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按操作類型分類的片段
  • 按藥物類型分類的片段
  • 按給藥途徑分類的片段
  • 藥理學片段
  • 按分發渠道分類的摘要
  • 區域摘要

第四章市場動態

  • 影響因素
    • 司機
      • 研發機構加強合作研究以解決抗菌素耐藥性 (AMR) 問題可推動市場增長
    • 約束因素
      • 新抗生素開發方面的挑戰阻礙了抗菌劑市場的增長
    • 機會
      • 增加臨床試驗的數量
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章俄烏戰爭分析

第 8 章按操作類型

  • 抑菌
  • 滅菌

第9章按藥物類型分類

  • β-內□胺系統
  • 氨基糖甘類
  • 大環內酯
  • 奎諾酮類
  • 四環素
  • 磺胺
  • 其他

第10章給藥途徑

  • 口語
  • 腸外
  • 其他

第 11 章藥物機制

  • 抑制細胞壁合成
  • 抑制蛋白質合成
  • 細胞膜的變化
  • 核酸合成抑製作用
  • 抗代謝作用

第 12 章分銷渠道

  • 零售藥房
  • 醫院藥房
  • 在線藥店

第13章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第14章競爭格局

  • 競爭場景
  • 市場份額分析
  • 併購分析

第十五章公司簡介

  • 輝瑞公司
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展
  • Sanofi S.A.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Novartis AG
  • Bristol Myers Squibb Company
  • GlaxoSmithKline Plc
  • Eli Lilly and Company
  • Shionogi & Co., Ltd.

第16章 附錄

簡介目錄
Product Code: PH1511

Market Overview

The global antibacterial drugs market reached US$ 43,857.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 63,326.8 million by 2030. The global antibacterial drugs market is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030). Major regional players, such as Shionogi & Co., Ltd., Savior Lifetec, Pfizer Inc., and Spero Therapeutics, among others are focusing the new product launches to increase their sales.

For instance, in February 2023, Japanese pharma firm Shionogi launched an anti-bacterial drug in Denmark. FETCROJA (cefiderocol) is now available in Denmark for treating infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options. This launch in Denmark is an important step in rapidly expanding access to cefiderocol across Europe, where we see an increasing trend in the number of antibiotic-resistant infections enhancing the global antibacterial drugs market.

Antibacterial drugs are derived from bacteria or molds and work by inhibiting cell wall production, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes. Antibacterial drugs, which include phenoxymethylpenicillin and penicillin V, are used to treat bacteria-related disorders. However, it doesn't treat viral infections such as colds, flu, and most coughs.

Furthermore, rising preclinical development pipelines in antibacterial agents, increasing FDA approvals, and increasing partnerships by key market players are the factors that are expected to drive the antibacterial drugs market growth over the forecast period.

Market Dynamics

The increasing collaborations by R&D organizations to address antimicrobial resistance (AMR) drives market growth

According to the Global Antibiotic Research and Development Partnership (GARDP), antibiotic resistance develops when bacteria change over time and no longer respond to treatment. Every year, millions of people suffer from antibiotic resistance, and almost 1.3 million people die. Moreover, the World Health Organisation has identified antibiotic resistance as one of the top ten global health threats and it is spreading globally as a pandemic of drug-resistant infections.

On March 9, 2023, the Global Antibiotic Research and Development Partnership (GARDP) and the University of Liverpool signed a Memorandum of Understanding (MOU) to collaborate on new projects to address antimicrobial resistance (AMR) for the benefit of public health.

Similarly, on April 3, 2023, the World Health Organization and GARDP invited manufacturers to apply to develop cefiderocol, an antibiotic used to treat multidrug-resistant bacterial infections. This is the first time the WHO Prequalification of Medicines Programme (PQP) has included multiple bacterial infections in its work. The PQP has extended an invitation to help initiatives promote the affordability and availability of multidrug-resistant bacteria therapy.

Challenges in developing new antibiotics are hampering the growth of the antibacterial drugs market

Discovering and creating new antibiotics is difficult since the research and development process is time-consuming, costly, and frequently fails. For instance, a new antibiotic can take 10-15 years and more than $1 billion to be developed. Moreover, the final phase of trials and after an initial product launch can account for 80% of the total R&D spend on a new drug, thereby inhibiting the antibacterial drug market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the antibacterial drug market. Hospitals and clinics have delayed or postponed non-emergency appointments, leading to fewer patients receiving proper treatment. Additionally, patients with bacterial infections may have been reluctant to seek medical attention due to fears of contracting COVID-19. As a result, revenue in the antibacterial drugs market has decreased, but they are still used for COVID, ensuring the market's steady growth during the forecast period.

Russia-Ukraine Conflict Analysis

The Ukrainian healthcare system is facing issues due to the Russian invasion, with many facilities destroyed and limited availability due to a shortage of skilled medical staff. According to the national statistics, the invaders have damaged 505 pharmacies in Eastern Ukraine, 47 of which were destroyed, and are blocking humanitarian aid provided by the Ukrainian government or other countries.

Besides, the volume of pharmacy sales doubled in the first 11 days of the Russian invasion due to large amounts of medications purchased by patients with chronic conditions. The top most often bought medicines were antiinflammatory and antirheumatic products, C09, analgesics, psychoanaleptics, diabetes drugs, and antibacterials for systemic use.

The Ukrainian pharmaceutical market has seen a significant drop in sales since March 2022, with 11% in March, 32% in April, and 24% in May and June compared to the same period of 2021. The decline is due to migration, occupation, medical humanitarian aid, and a drop in the income of the population. The downward trend began just after a substantial growth of the market before the war, with 31% in January and 45% in February.

Segment Analysis

The global antibacterial drugs market is segmented based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region.

The oral segment is expected to hold a dominant position in the market over the forecast period.

The oral segment accounted for the highest market stake accounting for approximately 48.8% of the antibacterial drugs market in 2022. Oral administration is the most practical and economical way to administer antibiotics, but it can be unpredictable in certain people. Oral therapy is used when it is tolerable and provides a sufficient therapeutic effect, while parenteral therapy is reserved for patients with difficulty having oral medicines or needing higher antimicrobial activity.

Moreover, oral administration over intravenous administration is beneficial due to the absence of thrombophlebitis and cannula-related infections, reduced drug costs, and decreased hidden costs. It can also make early hospital discharge or discharge straight from the emergency room possible.

For instance, oral antibiotics can treat uncomplicated UTIs, but readmission rates should not be lower than intravenous antibiotics. The bioavailability of oral antibiotics is an important factor in determining the effectiveness of intravenous drugs, as they may be substituted depending on the condition and drug penetration. Antibiotics such as Clindamycin, Fluconazole, Metronidazole, Sulfamethoxazole/trimethoprim, and Doxycline are commonly administered orally. Therefore, this segment will boost the global antibacterial drugs market growth over the forecast period.

Geographical Analysis

The merger and acquisition strategy by the key market players is to dominate the North American region.

North America is expected to dominate the worldwide antibacterial drugs market, accounting for around 1/3rd of this market, with the U.S. being the major contributor. For instance, in May 2022, Entasis Therapeutics, an antibiotic biotech, was acquired by Innoviva. On a fully diluted basis, the transaction values Entasis' stock at $113 million. Entasis' flagship medicine, SUL-DUR, outperformed an existing treatment in phase 3 clinical trial last year and is scheduled for FDA approval in mid-2022. SUL-DUR is a targeted antibiotic.

Competitive Landscape

The major global players in the market include: Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Shionogi & Co., Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, Bristol Myers Squibb Company, and Novartis AG, among others.

Why Purchase the Report?

  • To visualize the global antibacterial drugs market segmentation based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of antibacterial drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global antibacterial drugs market report would provide approximately 77 tables, 76 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Action Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Drug Mechanism
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing collaborations by R&D organizations to address antimicrobial resistance (AMR) drives market growth
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges in developing new antibiotics are hampering the growth of the antibacterial drugs market
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing number of clinical trials
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Action Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 8.1.2. Market Attractiveness Index, By Action Type
  • 8.2. Bacteriostatic*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Bactericidal

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Beta-lactams*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Aminoglycosides
  • 9.4. Macrolides
  • 9.5. Quinolones
  • 9.6. Tetracyclines
  • 9.7. Sulfonamide
  • 9.8. Others

10. By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Oral*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Parenteral
  • 10.4. Others

11. By Drug Mechanism

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 11.1.2. Market Attractiveness Index, By Drug Mechanism
  • 11.2. Inhibition of Cell Wall Synthesis*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Inhibition of Protein Synthesis
  • 11.4. Alteration of Cell Membranes
  • 11.5. Inhibition of Nucleic Acid Synthesis
  • 11.6. Antimetabolite Activity

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Retail Pharmacies*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Hospital Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.8.1. The U.S.
      • 13.2.8.2. Canada
      • 13.2.8.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.8.1. Germany
      • 13.3.8.2. The U.K.
      • 13.3.8.3. France
      • 13.3.8.4. Italy
      • 13.3.8.5. Spain
      • 13.3.8.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.8.1. Brazil
      • 13.4.8.2. Argentina
      • 13.4.8.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.8.1. China
      • 13.5.8.2. India
      • 13.5.8.3. Japan
      • 13.5.8.4. Australia
      • 13.5.8.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Pfizer Inc.*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Sanofi S.A.
  • 15.3. Bayer AG
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Dr. Reddy's Laboratories Ltd.
  • 15.6. Novartis AG
  • 15.7. Bristol Myers Squibb Company
  • 15.8. GlaxoSmithKline Plc
  • 15.9. Eli Lilly and Company
  • 15.10. Shionogi & Co., Ltd.

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us